22
Participants
Start Date
February 25, 2016
Primary Completion Date
December 12, 2018
Study Completion Date
December 12, 2018
Lenalidomide
Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
Dexamethasone
Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Hospital Garcia Orta, E.P.E., Almada
Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora
Hospital Central de Faro, Faro
Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon
Centro Hospitalar Lisboa Central, EPE - Hospital de Sto. Ant. Capuchos, Lisbon
Fundação Champalimaud, Lisbon
Centro Hospitalar Lisboa Norte, EPE - Hospital Santa Maria, Lisbon
Centro Hospitalar do Porto - Hospital de Santo António, Porto
Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto
Centro Hospitalar de São João, EPE - Hospital de São João, Porto
Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia
Hospital de São Teotónio, E.P.E., Viseu
Lead Sponsor
Celgene
INDUSTRY